Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Infliximab for maintenance of remission in Crohn's disease

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD012609Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 22 March 2017see what's new
Type:
  1. Intervention
Stage:
  1. Protocol
Cochrane Editorial Group:
  1. Cochrane Gut Group

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Robert Battat

    Division of Gastroenterology, Jewish General Hospital, Montreal, Canada

    Division of Gastroenterology, McGill University Health Centre, Montreal, Canada

  • Navjot Deol

    Department of Medicine, University of Western Ontario, London, Canada

  • Tran M Nguyen

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

  • Claire E Parker

    Robarts Clinical Trials, London, Canada

  • Reena Khanna

    Department of Medicine, University of Western Ontario, London, Canada

    Robarts Clinical Trials, London, Canada

  • Brian G Feagan

    Department of Medicine, University of Western Ontario, London, Canada

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

    Robarts Clinical Trials, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

  • Vipul Jairath

    Correspondence to: Department of Medicine, University of Western Ontario, London, Canada

    [email protected]

    Robarts Clinical Trials, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

Contributions of authors

All authors were involved in the development of this protocol.

Declarations of interest

Robert Battat, Navjot Deol, Tran M Nguyen and Claire E Parker have no known conflicts.

Reena Khanna has received honoraria from AbbVie, Jansen, and Takeda for consultancy. All of these activities are outside the submitted work.

Brian G Feagan has received fee(s) from Abbott/AbbVie, Amgen, Astra Zeneca, Avaxia Biologics Inc., Bristol‐Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring, JnJ/Janssen, Merck, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, Tillotts Pharma AG, UCB Pharma for Board membership; fee(s) from Abbott/AbbVie, Actogenix, Albireo Pharma, Amgen, Astra Zeneca, Avaxia Biologics Inc., Axcan, Baxter Healthcare Corp., Boehringer‐Ingelheim, Bristol‐Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Merck, Millennium, Nektar, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, Tillotts, UCB Pharma, Vertex Pharma, Warner‐Chilcott, Wyeth, Zealand, and Zyngenia for consultancy; and lecture fee(s) from: Abbott/AbbVie, JnJ/Janssen, Takeda, Warner‐Chilcott, and UCB Pharma. All of these activities are outside the submitted work.

Vipul Jairath has received scientific advisory board fees from Abbvie, Sandoz, Ferring and Janssen; speaker's fees from Takeda and Ferring; and travel support for conference attendance from Vifor pharmaceuticals.

Acknowledgements

Partial funding for the Cochrane IBD Group (April 1, 2016 ‐ March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC).

Version history

Published

Title

Stage

Authors

Version

2024 Feb 19

Infliximab for maintenance of medically‐induced remission in Crohn's disease

Review

Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Arni Sarian, Gordon William Moran

https://doi.org/10.1002/14651858.CD012609.pub2

2017 Mar 22

Infliximab for maintenance of remission in Crohn's disease

Protocol

Robert Battat, Navjot Deol, Tran M Nguyen, Claire E Parker, Reena Khanna, Brian G Feagan, Vipul Jairath

https://doi.org/10.1002/14651858.CD012609

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.